(0.11%) 5 254.35 points
(0.12%) 39 807 points
(-0.12%) 16 379 points
(-0.07%) $83.11
(-0.62%) $1.752
(0.73%) $2 254.80
(0.74%) $25.10
(0.21%) $923.00
(-0.02%) $0.926
(-0.08%) $10.83
(-0.11%) $0.791
(-0.21%) $92.38
@ $4.83
Issued: 14 Feb 2024 @ 09:35
Return: -93.39%
Live Chart Being Loaded With Signals
LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, respiratory, opthalmology, and inflammatory diseases in China and other Asian countries...
Stats | |
---|---|
Today's Volume | 2.48M |
Average Volume | 963 531 |
Market Cap | 34.47M |
EPS | $0 ( 2024-03-25 ) |
Next earnings date | ( $0 ) 2024-05-09 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.390 |
ATR14 | $0.00600 (1.80%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-15 | Poukalov Konstantin | Buy | 36 300 | Ordinary Shares |
2024-02-15 | Poukalov Konstantin | Sell | 19 218 | Ordinary Shares |
2024-02-15 | Poukalov Konstantin | Sell | 36 300 | Stock Option (Right to Buy) |
2024-02-15 | Perceptive Advisors Llc | Buy | 36 300 | Ordinary Shares |
2024-02-15 | Perceptive Advisors Llc | Sell | 19 218 | Ordinary Shares |
INSIDER POWER |
---|
73.97 |
Last 77 transactions |
Buy: 50 859 501 | Sell: 7 415 331 |
Volume Correlation
LianBio Correlation
10 Most Negative Correlations | |
---|---|
EMBC | -0.83 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
LianBio Correlation - Currency/Commodity
LianBio Financials
Annual | 2022 |
Revenue: | $0 |
Gross Profit: | $-1.00M (0.00 %) |
EPS: | $-1.020 |
Q3 | 2023 |
Revenue: | $0 |
Gross Profit: | $-300 018 (0.00 %) |
EPS: | $-0.220 |
Q2 | 2023 |
Revenue: | $0 |
Gross Profit: | $-296 781 (0.00 %) |
EPS: | $-0.200 |
Q1 | 2023 |
Revenue: | $0 |
Gross Profit: | $-323 366 (0.00 %) |
EPS: | $-0.220 |
Financial Reports:
No articles found.
LianBio
LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, respiratory, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor for ulcerative colitis and Crohn's disease; NX-13 for ulcerative colitis; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03, an eye solution for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators